PT  - JOURNAL ARTICLE
AU  - Bhuvnesh Aggarwal
AU  - Sachin S. Goel
AU  - Joseph F. Sabik
AU  - Mehdi H. Shishehbor
TI  - The FREEDOM trial: In appropriate patients with diabetes and multivessel coronary artery disease, CABG beats PCI
AID  - 10.3949/ccjm.80a.13030
DP  - 2013 Aug 01
TA  - Cleveland Clinic Journal of Medicine
PG  - 515--523
VI  - 80
IP  - 8
4099  - http://www.ccjm.org/content/80/8/515.short
4100  - http://www.ccjm.org/content/80/8/515.full
SO  - Cleve Clin J Med2013 Aug 01; 80
AB  - The Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM) trial (N Engl J Med 2012; 367:2375–2384) was designed to resolve the long-standing debate over the optimal revascularization strategy in patients with diabetes mellitus and multivessel coronary artery disease. At a median follow-up of 3.8 years, the incidence of the primary outcome (a composite of death, myocardial infarction, and stroke) was significantly lower with bypass surgery than with percutaneous intervention.